Safety Reading Notes

Read safety context beside the research guide.

The GPR119 cannabinoid target source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 18426507

PubMed For Dummies Article

GPR119 cannabinoid target Evidence Review: the long-form source walk-through

Quick read
  • GPR119 cannabinoid target currently has 8 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 18426507
  • The evidence classes most visible in the row language are insufficient (6), mechanistic or pharmacological (1), and preliminary human (1). PMID 19413995
  • The study-design language most visible in the row language is Narrative or expert review (6), and Animal study (1). PMID 20353771
  • The repeated topics are GPR119 (8), which tells the reader where to start opening PubMed and DOI links. PMID 19285259

Start with the research question

GPR119 cannabinoid target is built from 8 source-backed evidence row(s) and 8 research source(s). The current evidence classes read as insufficient (6), mechanistic or pharmacological (1), and preliminary human (1), and the study-design language most often reads as Narrative or expert review (6), and Animal study (1). PMID 18426507

The row-level question is not simply whether GPR119 cannabinoid target is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are GPR119 (8). PMID 23074242

Human evidence 1 row

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 23074242

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 30787385

Mechanistic evidence 1 row

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 42144898

Limits and uncertainty 6 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 30537148

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 18426507

Where this page has the most source density

The largest bucket surfaced for this page is GPR119: insufficient. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is GPR119: mechanistic or pharmacological, which gives readers another way to see what the literature repeatedly circles. PMID 18426507

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 23074242

Bucket chapters: what the literature is circling

GPR119: insufficient

6 research sources 6 rows (963, 964, 965, 966, 969, 970) Evidence class: insufficient

This bucket summarizes source-backed rows focused on GPR119: insufficient. It currently draws from 6 research source(s), so the exact study type matters. PMID 18426507

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 18426507

  • Evidence row 963

    Endocannabinoids modulates GPR119; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signa... PMID 18426507

  • Evidence row 964

    Anandamide modulates GPR119; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology). PMID 19413995

GPR119: mechanistic or pharmacological

1 research source 967 Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on GPR119: mechanistic or pharmacological. It currently draws from 1 research source(s), so the exact study type matters. PMID 23074242

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 23074242

  • Evidence row 967

    Endocannabinoids modulates GPR119; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: GPR119 receptor activity, binding, signaling, metaboli... PMID 23074242

GPR119: preliminary human

1 research source 968 Evidence class: preliminary human

This bucket summarizes source-backed rows focused on GPR119: preliminary human. It currently draws from 1 research source(s), so the exact study type matters. PMID 30787385

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 30787385

  • Evidence row 968

    Endocannabinoids modulates GPR119; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharma... PMID 30787385

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (1 row(s)), mechanistic evidence (1 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 18426507

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 23074242

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 19413995
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 20353771
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 19285259

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 18426507

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 23074242

Source-reading checklist for GPR119 cannabinoid target

  1. Open the linked PubMed or DOI record. PMID 23074242
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 30787385
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 42144898
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 30537148
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 18426507

Source Notes

GPR119 cannabinoid target source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 963

    Endocannabinoids modulates GPR119; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology). PMID 18426507

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoids and nutrition.
  2. Evidence row 964

    Anandamide modulates GPR119; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology). PMID 19413995

    Evidence class: insufficient; Study design: Narrative or expert review. Source: N-acylethanolamines, anandamide and food intake.
  3. Evidence row 965

    Anandamide modulates GPR119; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology). PMID 20353771

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain.
  4. Evidence row 966

    Endocannabinoids modulates GPR119; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology). PMID 19285259

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance.
  5. Evidence row 967

    Endocannabinoids modulates GPR119; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology). PMID 23074242

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Regulation of GPR119 receptor activity with endocannabinoid-like lipids.
  6. Evidence row 968

    Endocannabinoids modulates GPR119; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology). PMID 30787385

    Evidence class: preliminary human. Source: Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer.
  7. Evidence row 969

    Endocannabinoids modulates GPR119; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology). PMID 42144898

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Fatty acid amide hydrolase (FAAH) and the endocannabinoid system in obesity: Mechanistic insights and pharmacological opportunities beyond incretin-based therapies.
  8. Evidence row 970

    Endocannabinoids modulates GPR119; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology). PMID 30537148

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review.